

CLS Q3 (Review) - Soft sales, but better quarters ahead

Redeye provides an update following CLS's Q3 2025 report. Sales came in well below our expectations; however, we believe this is only a temporary setback, with stronger quarters ahead. Following the report, we have made some estimate adjustments, resulting in a slightly revised fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

CLS Q3 (Review) - Soft sales, but better quarters ahead